RNA-seq analysis and in vivo experiments identified the protective effect of kaempferol on idiopathic pulmonary fibrosis by regulating the PPARG/TNC signaling pathway to reduce ECM deposition
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Kaempferol (KMP) effectively treats idiopathic pulmonary fibrosis (IPF) by reducing lung inflammation and collagen deposition. It targets the PPARG/TNC pathway, offering a new therapeutic approach for IPF.
Area Of Science
- Pulmonology
- Pharmacology
- Molecular Biology
Background
- Idiopathic pulmonary fibrosis (IPF) is a severe, age-related lung disease with limited treatment options.
- Kaempferol (KMP), a natural compound, exhibits anti-inflammatory and antioxidant properties, showing potential against fibrotic diseases.
Purpose Of The Study
- To investigate the therapeutic efficacy of Kaempferol (KMP) in a bleomycin-induced mouse model of idiopathic pulmonary fibrosis (IPF).
- To elucidate the underlying molecular mechanisms of KMP's action in treating IPF, focusing on the PPARG/TNC signaling pathway.
Main Methods
- Establishment of an IPF mouse model using bleomycin instillation.
- Assessment of KMP's effects on lung histology, inflammatory markers, and fibrotic indicators.
- Transcriptomic analysis to identify key signaling pathways regulated by KMP.
- Molecular docking and immunofluorescence to validate the interaction between KMP, PPARG, and TNC.
Main Results
- KMP treatment significantly improved body weight, reduced inflammatory infiltration and collagen deposition in IPF mice.
- KMP downregulated key fibrotic markers (e.g., α-SMA, Col3a1) and inflammatory cytokines (e.g., TNF-α, IL-6).
- Transcriptomic and experimental data revealed KMP regulates the PPARG/TNC pathway, inhibiting extracellular matrix deposition and ECM-receptor interactions.
Conclusions
- Kaempferol demonstrates significant therapeutic potential for idiopathic pulmonary fibrosis (IPF) by mitigating lung inflammation and fibrosis.
- The PPARG/TNC signaling pathway is identified as a crucial mechanism through which KMP exerts its protective effects in IPF.
- These findings suggest KMP as a promising candidate for developing novel IPF therapies.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
